Artivion, Inc. (NYSE:AORT) Insider John E. Davis Sells 15,100 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 15,100 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $356,511.00. Following the completion of the sale, the insider now directly owns 208,778 shares of the company’s stock, valued at approximately $4,929,248.58. This trade represents a 6.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Artivion Price Performance

Shares of NYSE:AORT opened at $23.58 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The firm has a fifty day moving average price of $28.83 and a 200 day moving average price of $27.77. Artivion, Inc. has a fifty-two week low of $19.11 and a fifty-two week high of $32.33. The firm has a market cap of $991.37 million, a price-to-earnings ratio of -1,178.85 and a beta of 1.79.

Artivion (NYSE:AORT) last issued its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. As a group, sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Artivion

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC grew its stake in shares of Artivion by 30.8% in the 4th quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock worth $1,021,000 after buying an additional 8,404 shares in the last quarter. Tidal Investments LLC grew its stake in shares of Artivion by 14.5% in the 4th quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock worth $5,141,000 after buying an additional 22,804 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Artivion in the 4th quarter worth $64,000. Point72 Asset Management L.P. purchased a new position in shares of Artivion in the 4th quarter worth $5,573,000. Finally, ProShare Advisors LLC grew its stake in shares of Artivion by 44.7% in the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock worth $341,000 after buying an additional 3,683 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AORT shares. Stifel Nicolaus reduced their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Needham & Company LLC dropped their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. Finally, JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.